Developing Innovative Cancer Immunotherapies

Learn about our science

Press Releases

July 17, 2018 in Press Releases

Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers

Read More
July 12, 2018 in Press Releases

Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

Read More
June 26, 2018 in Press Releases

Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies

Read More

Pipeline

AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.

AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.

AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.

AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.

Go to Pipeline

Arcus has significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership